state which may ameliorate organ damage including acute cardiac injury (Convertino et al., 2020)
Janus kinase (JAK) inhibitors • Ruxolitinib, tofacitinib, baricitinib are proposed to be beneficial in controlling excessive IL-6 signaling through STAT-1 and STAT-3 pathways (Alijotas-Reig et al., 2020; Convertino et al., 2020; Richardson et al., 2020; Rizk et al., 2020)
Anti-interleukin-1 • Anakinra, a modified IL-1 rece